Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age.1 Guidelines for the treatment of AD have recently been updated.2-5
Skin hydration (bath/shower) followed immediately by application of an emollient is...
- In Brief: Extended Duration of Use for Nexplanon
- Addendum: Urinary Incontinence with Second-Generation Antipsychotic Drugs
- Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis (online only)
- Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis (online only)
- Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections
- A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
- Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
- In Brief: Label Changes for Menopausal Hormone Therapy Products
- In Brief: Removal of Suicidality Warning from GLP-1 Agonists for Weight Management
- Denileukin Diftitox (Lymphir) for Cutaneous T-Cell Lymphoma (online only)
- Sevabertinib (Hyrnuo) for NSCLC (online only)
RELEASE
Oral semaglutide 1.5-, 4-, and 9-mg tablets, which were previously approved by the FDA (but never marketed) as the R2 formulation of Rybelsus, have now been approved as Ozempic (see Table 1). Both the original R1 formulation of Rybelsus (3-, 7-, and 14-mg tablets) and the renamed Ozempic tablets are FDA-approved for treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at risk for these events.1,2 The R1 (Rybelsus) and R2 (Ozempic) formulations are not interchangeable on a mg-per-mg basis; Ozempic tablets contain inactive ingredients that enhance drug absorption and have greater bioavailability than Rybelsus R1 tablets.
The name change capitalizes on the brand-name recognition of Ozempic, which has been available for subcutaneous administration in …